M. Gross et al., Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, ANTI-CANC D, 10(6), 1999, pp. 533-536
Hemolytic uremic syndrome (HUS) is a rare clinical and biological entity. H
US has been reported after several anticancer chemotherapies and most often
after mitomycin C-based chemotherapy regimens. Little information is avail
able concerning the occurrence and outcome of this syndrome after administr
ation of more recent chemotherapeutic agents. We present a case of HUS in a
n advanced ovarian cancer patient treated with carboplatin end gemcitabine,
and described its favorable outcome after chemotherapy interruption and su
pportive care with a 1 year follow-up. [(C) 1999 Lippincott Williams & Wilk
ins.].